Transl Clin Pharmacol.  2014 Jun;22(1):3-7.

CYP3A5*3 Polymorphism and Its Clinical Implications and Pharmacokinetic Role

• Park JY
• Cha YJ
• Kim KA

Abstract

The cytochrome P450 (CYP) 3A subfamily is estimated to participate in the biotransformation of 50% of the currently prescribed drugs. Four members of the CYP3A subfamily have been identified in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. Initial data suggested that CYP3A5 accounts for only a small proportion of the total hepatic CYP3A in about 20% of samples, but it was later revealed that CYP3A5 represents more than 50% of the total CYP3A amount in some individuals. Several genetic variants have been described for the CYP3A5 gene, of which the CYP3A5*3 allele (gA6986G), the most common form and leading to the loss of CYP3A5 activity, has been extensively investigated in the aspect of pharmacokinetics and disease risk. This review summarized the molecular characteristics of the CYP3A5 gene, and discusses the association of the CYP3A5*3 polymorphism with disease risks such as cancer and hypertension, along with its role in the pharmacokinetics of CYP3A substrates.

Keyword

CYP3A5*3; Cytochrome P450; Cancer; Pharmacokinetics; Pharmacogenetics

MeSH Terms

Alleles
Biotransformation
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System
Humans
Hypertension
Pharmacogenetics
Pharmacokinetics
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System

Reference

References

1. Wang K, Chen S, Xie W, Wan YJ. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol. 2008; 75:2204–2213.

2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999; 286:487–491.

3. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6:1–42.

4. Kuehl P1. Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001; 27:383–391.

5. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver micro-somes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994; 270:414–423.

6. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem. 2002; 277:24280–24288.

7. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun. 2001; 281:1349–1355.

8. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001; 11:111–121.

9. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11:773–779.

10. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol. 1990; 38:207–213.

11. Jounaïdi Y, Guzelian PS, Maurel P, Vilarem MJ. Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem Biophys Res Commun. 1994; 205:1741–1747.

12. Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhasselt P, Luyten W, et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics. 2000; 10:415–424.

13. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics. 2003; 13:461–472.

14. Jounaïdi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun. 1996; 221:466–470.

15. Lakhman SS, Ma Q, Morse GD. Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics. 2009; 10:1323–1339.

16. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12:928–932.

17. Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, et al. CYP3A5∗3 and CYP3A4∗1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007; 29:412–416.

18. Dally H, Bartsch H, Jäger B, Edler L, Schmezer P, Spiegelhalder B, et al. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 2004; 207:95–99.

19. Balram C, Zhou Q, Cheung YB, Lee EJ. CYP3A5∗3 and ∗6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol. 2003; 59:123–126.

20. Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5∗3 and ∗6, in a Japanese population. Pharmacogenetics. 2002; 12:331–334.

21. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos. 2001; 29:1205–1209.

22. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, et al. CY-P3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos. 2005; 33:884–887.

23. Lee SJ, Goldstein JA. Functionally defective or altered CYP3A4 and CY-P3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005; 6:357–371.

24. Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P, et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol. 1992; 262:F927–F931.

25. Ghosh S, Grogan WM, Basu A, Watlington C. Renal corticosterone 6 beta-hydroxylase in the spontaneously hypertensive rat. Biochim Biophys Acta. 1993; 1182:152–156.

26. Cui JS, Hopper JL, Harrap SB. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension. 2003; 41:207–210.

27. Rais N, Hussain A, Chawla YK, Kohli KK. Association between urinary 6b-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population. Exp Ther Med. 2013; 5:527–532.

28. Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, et al. Association between the CYP3A5 genotype and blood pressure. Hypertension. 2005; 45:294–298.

29. Zhang YP, Zuo XC, Huang ZJ, Cai JJ, Wen J, Duan DD, et al. CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens. 2014; 28:145–149.

30. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CY-P3A5 expression. Pharmacogenomics. 2009; 10:1017–1024.

31. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002; 54:1271–1294.

32. Islam MS, Mostofa AG, Ahmed MU, Bin Sayeed MS, Hassan MR, et al. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population. Tumour Biol. 2014; 35:1671–1678.

33. Wang BS, Liu Z, Xu WX, Sun SL. CYP3A5∗3 polymorphism and cancer risk: a metaanalysis and meta-regression. Tumour Biol. 2013; 34:2357–2366.

34. Kristiansen W, Haugen TB, Witczak O, Andersen JM, Fosså SD, Aschim EL. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility. Int J Androl. 2011; 34:77–83.

35. Gervasini G, García-Martín E, Ladero JM, Pizarro R, Sastre J, Martínez C, et al. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients. BMC Cancer. 2007; 7:118.

36. Dandara C, Ballo R, Parker MI. CYP3A5 genotypes and risk of oesophageal cancer in two South African populations. Cancer Lett. 2005; 225:275–282.

37. Rao DN, Manjula G, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. Association of CYP3A5∗3 polymorphism with development of acute leukemia. Indian J Hum Genet. 2011; 17:175–178.

38. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep. 2002; 9:327–329.

39. Feng WX, Liu F, Gu Y, Jiao WW, Sun L, Xiao J, et al. Functional polymorphisms in CYP2C19 & CYP3A5 genes associated with decreased susceptibility for paediatric tuberculosis. Indian J Med Res. 2012; 135:642–649.

40. Du J, Xu Y, Duan S, Zhang A, Xuan J, Wang L, et al. A case-control association study between the CYP3A4 and CYP3A5 genes and schizophrenia in the Chinese Han population. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33:1200–1204.

41. Jia Y, Yu X, Zhang B, Yuan Y, Xu Q, Shen Y, et al. No association between polymorphisms in three genes of cytochrome p450 family and paranoid schizophrenia in northern Chinese Han population. Eur Psychiatry. 2004; 19:374–376.

42. Shimada T, Martin MV, Pruess-Schwartz D, Marnett LJ, Guengerich FP. Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. 1989; 49:6304–6312.

43. Le Moual N, Orlowski E, Schenker MB, Avignon M, Brochard P, Kauffmann F. Occupational exposures estimated by means of job exposure matrices in relation to lung function in the PAARC survey. Occup Environ Med. 1995; 52:634–643.

44. Piipari R, Savela K, Nurminen T, Hukkanen J, Raunio H, Hakkola J, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int J Cancer. 2000; 86:610–616.

45. Roberts-Thomson SJ, McManus ME, Tukey RH, Gonzalez FF, Holder GM. The catalytic activity of four expressed human cytochrome P450s towards benzo [a]pyrene and the isomers of its proximate carcinogen. Biochem Biophys Res Commun. 1993; 192:1373–1379.

46. Kaur-Knudsen D, Bojesen SE, Nordestgaard BG. CHRNA3 and CY-P3A5∗3 genotype, lung function and chronic obstructive pulmonary disease in the general population. Pharmacogenet Genomics. 2014; 24:220–229.

47. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5∗3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther. 2009; 34:569–574.

48. Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol. 2009; 29:272–277.

49. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CY-P3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007; 47:87–93.

50. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, et al. Effect of CYP3A5∗3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther. 2006; 79:590–599.

51. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol. 2006; 2:171–182.

52. Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm. 2006; 63:2340–2348.

53. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, et al. Effect of CYP3A5∗3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther. 2006; 80:646–656.